Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

United Therapeutics Wins Unituxin Approval, Pediatric Priority Review Voucher – With NIH Support

This article was originally published in The Pink Sheet Daily

Executive Summary

The National Cancer Institute conducted the clinical trials of Unituxin for treatment of pediatric high-risk neuroblastoma and teamed with United for manufacturing and commercialization.

You may also be interested in...



Neuroblastoma Drug Development: Potential Surrogate Endpoint Gets US FDA Panel Backing

Advisory committee supports further research on end-of-induction response as an early interim clinical endpoint for drugs in treatment of high-risk neuroblastoma. FDA has approved two drugs for this rare disease in children, who have a 40-50% chance of long-term survival.

AbbVie Pays Big For Priority Review Voucher; Is Venetoclax The Target?

With partner Genentech, AbbVie is planning to file the BCL-2 inhibitor for US and EU approval in tough-to-treat CLL later this year on the back of promising Phase II data.

Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078248

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel